144 related articles for article (PubMed ID: 7882335)
21. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
22. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
Costello JF; Berger MS; Huang HS; Cavenee WK
Cancer Res; 1996 May; 56(10):2405-10. PubMed ID: 8625319
[TBL] [Abstract][Full Text] [Related]
23. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
24. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
Zheng J; Hou P; Zhou C
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
[TBL] [Abstract][Full Text] [Related]
25. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
[TBL] [Abstract][Full Text] [Related]
26. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector.
Jin X; Nguyen D; Zhang WW; Kyritsis AP; Roth JA
Cancer Res; 1995 Aug; 55(15):3250-3. PubMed ID: 7614457
[TBL] [Abstract][Full Text] [Related]
27. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
He J; Allen JR; Collins VP; Allalunis-Turner MJ; Godbout R; Day RS; James CD
Cancer Res; 1994 Nov; 54(22):5804-7. PubMed ID: 7954404
[TBL] [Abstract][Full Text] [Related]
28. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.
Liggett WH; Sewell DA; Rocco J; Ahrendt SA; Koch W; Sidransky D
Cancer Res; 1996 Sep; 56(18):4119-23. PubMed ID: 8797577
[TBL] [Abstract][Full Text] [Related]
29. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
Hirama T; Miller CW; Wilczynski SP; Koeffler HP
Mod Pathol; 1996 Jan; 9(1):26-31. PubMed ID: 8821952
[TBL] [Abstract][Full Text] [Related]
30. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
Pollock PM; Yu F; Qiu L; Parsons PG; Hayward NK
Oncogene; 1995 Aug; 11(4):663-8. PubMed ID: 7651729
[TBL] [Abstract][Full Text] [Related]
31. Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
Srivenugopal KS; Ali-Osman F
Oncogene; 1996 May; 12(9):2029-34. PubMed ID: 8649864
[TBL] [Abstract][Full Text] [Related]
32. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Dec; 11(11):2455. PubMed ID: 8570198
[No Abstract] [Full Text] [Related]
33. Adenoviral p16/CDKN2 gene transfer to malignant glioma: role of p16 in growth, invasion, and senescence.
Kim SK; Wang KC; Cho BK; Lim SY; Kim YY; Oh CW; Chung YN; Kim CY; Lee CT; Kim HJ
Oncol Rep; 2003; 10(5):1121-6. PubMed ID: 12883667
[TBL] [Abstract][Full Text] [Related]
34. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
Harada H; Nakagawa K; Iwata S; Saito M; Kumon Y; Sakaki S; Sato K; Hamada K
Cancer Res; 1999 Aug; 59(15):3783-9. PubMed ID: 10446996
[TBL] [Abstract][Full Text] [Related]
35. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
Barrett MT; Sanchez CA; Galipeau PC; Neshat K; Emond M; Reid BJ
Oncogene; 1996 Nov; 13(9):1867-73. PubMed ID: 8934532
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
38. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
39. Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9.
Wu Q; Possati L; Montesi M; Gualandi F; Rimessi P; Morelli C; Trabanelli C; Barbanti-Brodano G
Int J Cancer; 1996 Mar; 65(6):840-6. PubMed ID: 8631601
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Herman JG; Jen J; Merlo A; Baylin SB
Cancer Res; 1996 Feb; 56(4):722-7. PubMed ID: 8631003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
